Management of severe asthma in children

Andrew Bush, Sejal Saglani

Children who are referred to specialist care with asthma that does not respond to treatment (problematic severe asthma) are a heterogeneous group, with substantial morbidity. The evidence base for management is sparse, and is mostly based on data from studies in children with mild and moderate asthma and on extrapolation of data from studies in adults with severe asthma. In many children with severe asthma, the diagnosis is wrong or adherence to treatment is poor. The first step is a detailed diagnostic assessment to exclude an alternative diagnosis (“not asthma at all”), followed by a multidisciplinary approach to exclude comorbidities (“asthma plus”) and to assess whether the child has difficult asthma (improves when the basic management needs, such as adherence and inhaler technique, are corrected) or true, therapy-resistant asthma (still symptomatic even when the basic management needs are resolved). In particular, environmental causes of secondary steroid resistance should be identified. An individualised treatment plan should be devised depending on the clinical and pathophysiological characterisation. Licensed therapeutic approaches include high-dose inhaled steroids, the Symbicort maintenance and reliever (SMART) regimen (with budesonide and formoterol fumarate), and anti-IgE therapy. Unlicensed treatments include methotrexate, azathioprine, ciclosporin, and subcutaneous terbutaline infusions. Paediatric data are needed on cytokine-specific monoclonal antibody therapies and bronchial thermoplasty. However, despite the interest in innovative approaches, getting the basics right in children with apparently severe asthma will remain the foundation of management for the foreseeable future.

Introduction

Although the evidence base for the treatment of mild-to-moderate asthma in children is expanding,1-2 paediatric asthma beyond stage 3 of the British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines Network (SIGN) guidelines1 has been the subject of few good-quality studies. Several reviews have been published4-9 but primary data are sparse. Reviews have emphasised the wide differential diagnosis in children, the need to involve the school, as well as the home, the role of viral infections,3 and the importance of monitoring longitudinal change in lung function.4 Children with true therapy-resistant asthma constitute less than half of children referred with problematic severe asthma, and undergo detailed assessments of symptoms, spirometry, and inflammation, including invasive investigations such as bronchoscopy, before new therapies are used. This process helps to diagnose different forms of asthma: asthma, which is clinically characterised by poor control and multiple exacerbations, brittle asthma, with chaotic swings in peak flow, and severe asthma with fungal sensitisation, and persistent airflow limitation. Pathologically, asthma is characterised on the basis of proximal luminal inflammation, as persistently eosinophilic, neutrophilic, or paucicellular asthma. In this Review, we focus on children of school age and adolescents. We are not aware of any randomised controlled trials of treatment in true, therapy-resistant paediatric asthma, so we have based recommendations on personal practice, with cautious extrapolation from published papers on adult severe asthma and paediatric mild-to-moderate asthma. Many cases of apparently treatment-unresponsive asthma arise because the basics (eg, adherence, inhaler technique, dose and frequency, minimisation of allergen, and smoke exposure) have not been dealt with correctly.2-9 In a study in which two add-on regimens in symptomatic children were compared, despite being prescribed at least 400 μg budesonide per day plus a long-acting β2 agonist, only 55 of 292 children assessed for eligibility could be randomised; of the other 237 children, 89 were non-adherent and 59 had mild or no asthma.7 In two well designed negative trials8,9 in which the use of fractional exhaled nitric oxide (FeNO) was studied as an add-on to standard monitoring of uncontrolled asthma, similar problems occurred. In the first study,1 in the run-in period when basic management was assessed, the improvements in both groups were so great that there was little, if any, scope for further improvement. In the second study,1 in which detailed FeNO telemonitoring was used to adjust treatment, with intensive three weekly telephone contacts in control and active groups, both groups had the same amount of improvement in symptoms and reduction in inhaled corticosteroids. Despite guideline-based therapy and measurement of inflammatory markers (“inflammometry”), leading to excellent baseline control, many children still had severe exacerbations that required oral steroid therapy. This failure to control exacerbations indicates the dissociation between control and
analyses will hopefully soon enable us to improve on unrefined, and novel biomarkers and mathematical panel 2, listed in no particular order. These categories are divided into one or more of the categories provided in future risk after an admission to intensive care.

Symptoms (either exacerbations or poor control, or both), treatment will probably differ between them; for example, clinical categorisation. We use these groupings because to have treatment reduced, unlike in the other categories. Children with this type of asthma have a different and less diverse presentation than do adults. They use healthcare services more often, despite the prescription of at least two controller therapies, they have a high morbidity, including exacerbations, admissions to intensive care, and prednisolone use, most are atopic with multiple sensitisations, and, unlike in adults, there is a male preponderance.

**Domains of severity in paediatric asthma**

The four suggested domains of severity are given in panel 1. This classification assumes that acute exacerbations and baseline control, although overlapping, are distinct features, which we further discuss later. Referral to specialist care will usually be prompted by symptoms (either exacerbations or poor control, or both), concerns about safety of the amount of medication, and future risk after an admission to intensive care.

**Patterns of difficulty that trigger referral to specialist care**

The different problems that trigger referral were characterised in one study as either “chaotic” (more than 30% variability in spirometry) or “non-chaotic” (less than 15% variability). These characteristics can be broken down into one or more of the categories provided in panel 2, listed in no particular order. These categories are unrefined, and novel biomarkers and mathematical analyses will hopefully soon enable us to improve on clinical categorisation. We use these groupings because treatment will probably differ between them; for example, children with persistent airflow limitation might be able to have treatment reduced, unlike in the other categories.

**The entry label: “problematic severe asthma”**

When the child is initially referred, it will not be clear whether (1) the diagnosis is wrong (“not asthma at all”), and a diagnostic re-evaluation (not discussed in this Review) is essential; (2) the asthma is mild, but exacerbated by one or more comorbidities (“asthma plus”); (3) whether this is “difficult-to-treat asthma” because of potentially reversible factors such as poor adherence to treatment or poor inhalation technique; or (4) they have true “severe, therapy-resistant asthma”, which remains refractory to treatment even when reversible factors have been taken into account. There can be overlap between the second and third group. We use the general term “problematic severe asthma” to encompass these four categories. Children with this type of asthma have a different and less diverse presentation than do adults. They use healthcare services more often, despite the prescription of at least two controller therapies, they have a high morbidity, including exacerbations, admissions to intensive care, and prednisolone use, most are atopic with multiple sensitisations, and, unlike in adults, there is a male preponderance.

### Panel 1: Domains of asthma severity in children

1. Level of current prescribed treatment
2. Level of current baseline control of asthma over at least the preceding month (note there is no evidence for the definition of this time period)
3. Immediate past burden of asthma exacerbations, including number and severity (possibly over past 6 months, again there is no evidence for this definition)
4. Future risk of complications, including: risk of failure of normal postnatal airway growth; risk of future loss of asthma control; risk of future exacerbations; risk of phenotype change from episodic, viral, to multi-trigger (mainly in pre-school children); and risk of harm from drugs

Exacerbations, and that the problem of exacerbations merits more attention, which we further discuss later.

Thus, for a child with apparently severe asthma, the first step is to confirm the diagnosis and ensure that basic management strategies are in place. These strategies should affirm that an appropriate drug delivery device is used, that adherence to treatment is good, and that exposure to environmental triggers is minimised.

### The first step: is it likely to be true severe, therapy-resistant asthma?

As a first step, we recommend a detailed re-evaluation, including both a hospital-based session and a nurse-led home visit. The current evidence base for the benefit of many measurements is poor, and much work is aimed at prospectively generating research data.

### The hospital visit

We use a detailed checklist on symptom patterns and psychosocial factors. Because there is an imperfect concordance between skin prick tests and radioallergosorbent tests (76–83%), allergic sensitisation to Aeroallergens (grass and tree pollen, house dust mite, cockroach, cat, dog), fungi (Aspergillus fumigatus, Alternaria alternata, Cladosporium herbarum, Penicillium chrysogenum, Candida albicans, Trichophyton mentagrophytes, Botrytis cinerea), and food allergens (peanut, milk, egg), as well as any others clinically indicated, is assessed by both tests. We measure FeNO, spirometry, and bronchodilator response, and, if FEV₁ is more than 70% predicted, induced sputum cell counts. Saliva is collected for cotinine concentrations as an objective measure of exposure to tobacco smoke. If prednisolone or theophylline have been prescribed, blood concentrations of the drugs are measured. An appointment is made for the specialist respiratory nurse to visit the home.

### The role of spirometry, bronchodilator responsiveness, and bronchial challenge testing

Unlike in adults, use of spirometry is poorly discriminatory between asthma of different severities in children. Use of spirometry is helpful as part of the definition of an exacerbation and for monitoring progression of lung growth over time. Epidemiological evidence is that, for groups, spirometry data in severe asthma can be tracked over decades. For individuals, there is evidence that, despite apparently good control of symptoms with inhaled corticosteroids, lung function can deteriorate over time. In a post-hoc analysis, this deterioration was associated with the exacerbating...
Review

Panel 2: The different problems that trigger referral

- Persistent (most days, for at least 3 months) chronic symptoms (which prompt use of short-acting β2 agonists three times per week or more) of airway obstruction despite high-dose inhaled corticosteroid (beclometasone equivalent 800 μg per day) and trials of add-on drugs (long-acting β2 agonists, leukotriene receptor antagonists, and oral theophylline in a low, anti-inflammatory dose). The inhaled corticosteroid threshold is arbitrary. Although the plateau of the inhaled corticosteroid dose-response curve is low for mild asthma (perhaps even 200 μg per day 2), it might be higher in patients with steroid resistance. A poor correlation between symptoms and parental administration of β2 agonists.  

- Type 1 brittle asthma* (chaotic swings in peak flow in most days over a period of months). There are insufficient paediatric data to give a more precise definition of this form of asthma; nearly all data are from studies in adults. 

- Recurrent severe asthma exacerbations that have required at least one admission to an intensive care unit, at least two hospital admissions with intravenous treatment, or two or more courses of oral steroids during the past year despite therapy as described above for persistent chronic symptoms.  

- Type 2 brittle asthma* (sudden and catastrophic attack after apparently good control); again, most data come from adults.  

- Persistent airflow limitation: after oral steroid, the post-bronchodilator Z score is less than –1.96 for forced expired volume in 1 s (FEV1) with appropriate reference populations.  

- The necessity of prescription of oral steroids daily or every other day.  

phenotype, but only in patients not treated with inhaled corticosteroids. This study requires prospective confirmation. Bronchodilator responsiveness might be used as part of the diagnostic process and to define persistent airflow limitation (as mentioned earlier). There are few studies on the role of bronchial challenge testing as a clinical tool in problematic severe asthma. In many children, this testing is too risky because of poor lung function and extreme bronchial hyper-reactivity. Bronchial challenge testing might have a role in the diagnostic assessment; in a child with normal spirometry and reported severe symptoms, a negative challenge would make uncontrolled asthma unlikely. The role of this testing in children with persistent airflow limitation or obliterative bronchiolitis, as part of confirmation that further escalation of therapy is not useful, is not clear.

The role of high-resolution CT scanning

High-resolution CT scanning (HRCT) might be done as part of the diagnostic assessment, if, for example, the patient is non-atopic or if bronchiectasis is suspected. However, in adult studies, bronchial wall dilatation is common in severe asthma, and it is important not to over-diagnose bronchiectasis. HRCT scans might not help to distinguish severe asthma from obliterative bronchiolitis. In adults, there is evidence that HRCT scans might be a useful biomarker of asthma severity, but the evidence is much less clear in children. In children, HRCT changes consistent with asthma are less apparent than those in adults, and bronchial wall thickening has no or only weak correlation with thickening of the reticular basement membrane and decreases in FEV1. Air trapping on HRCT might enable an estimate of distal airway disease, but has not been compared in severe asthma with sophisticated tests of distal airway function such as lung clearance index. We are not aware of any studies on the usefulness of HRCT scans as a longitudinal tool to monitor severe paediatric asthma, and the radiation risk of even low-dose HRCT in young children should be carefully considered. In summary, there is no evidence to recommend routine HRCT as a clinical test in true severe, therapy-resistant paediatric asthma.

The home visit

We have recently reported the use of home visits as part of the assessment of problematic severe asthma. Here, we discuss four areas that are assessed in home visits: adherence to treatment, exposure to tobacco smoke, allergens, and psychosocial factors. Asthma education is also an important part of this process. This approach might not be feasible in all cases, but in our experience, it enables the identification of important and potentially reversible factors in more than half of patients referred with problematic severe asthma.

Adherence to treatment

Most information comes from paediatric community-based studies and adults with severe asthma, rather than in children with severe asthma. In summary, adherence to treatment is often poor, and parents overestimate how much drug is being given. In our series of home visits of 71 patients, less than half the patients had picked up more than 80% of the required prescriptions, and nearly a third had picked up less than 50%, similar to that reported in previous work. Drugs were often past the expiry date. Even young children (20% of 7-year-olds and 50% of 11-year-olds) were left to take asthma treatments on the basis of an estimate of distal airway disease, but has not been compared in severe asthma with sophisticated tests of distal airway function such as lung clearance index. We are not aware of any studies on the usefulness of HRCT scans as a longitudinal tool to monitor severe paediatric asthma, and the radiation risk of even low-dose HRCT in young children should be carefully considered. In summary, there is no evidence to recommend routine HRCT as a clinical test in true severe, therapy-resistant paediatric asthma.

The role of high-resolution CT scanning

High-resolution CT scanning (HRCT) might be done as part of the diagnostic assessment, if, for example, the patient is non-atopic or if bronchiectasis is suspected. However, in adult studies, bronchial wall dilatation is common in severe asthma, and it is important not to over-diagnose bronchiectasis. HRCT scans might not help to distinguish severe asthma from obliterative bronchiolitis. In adults, there is evidence that HRCT scans might be a useful biomarker of asthma severity, but the evidence is much less clear in children. In children, HRCT changes consistent with asthma are less apparent than those in adults, and bronchial wall thickening has no or only weak correlation with thickening of the reticular basement membrane and decreases in FEV1. Air trapping on HRCT might enable an estimate of distal airway disease, but has not been compared in severe asthma with sophisticated tests of distal airway function such as lung clearance index. We are not aware of any studies on the usefulness of HRCT scans as a longitudinal tool to monitor severe paediatric asthma, and the radiation risk of even low-dose HRCT in young children should be carefully considered. In summary, there is no evidence to recommend routine HRCT as a clinical test in true severe, therapy-resistant paediatric asthma.
control in about half the patients. Another important use of prescription records is to identify which patients collect excessive prescriptions of short-acting β2 agonists; collecting six or more per year was associated with a poor outcome in a community-based study. 33

Environmental tobacco smoke
Data from many studies suggest that active smoking by adults with asthma leads to steroid resistance, 45–47 and exposure to passive smoke probably has the same effect. Symptoms are also likely to be exacerbated by a direct irritant effect. Exposure to passive smoke is common in asthmatic children; 45–47 the frequency of active smoking is unknown. In our series of home visits, 25% of children with problematic severe asthma were exposed to tobacco smoke. The mechanisms of tobacco smoke-induced steroid resistance have been researched mainly in adults. 48

Ongoing allergen exposure
Allergen exposure, at a level insufficient to cause acute deterioration, leads to increased airway inflammation, bronchial responsiveness, 49 and steroid resistance via interleukin-2-dependent and interleukin 4-dependent mechanisms in adults. High allergen exposure in the home and allergic sensitisation is a cause of acute exacerbations of asthma in children. 27 Allergen exposure in schools might also be important, 72 but this possibility is an even more difficult area in which to intervene. Low-dose exposure to cat allergen on the clothes of classmates at school is sufficient to cause deterioration of asthma. The aeroallergens likely susceptible to intervention are pets, cockroaches, moulds, and house dust mites. House dust mites are a controversial area because, although there is little evidence for routine use of avoidance measures for most children sensitised to these aeroallergens, no study has convincingly evaluated whether there will be benefit in children with severe asthma, the group that might be most likely to comply with the demanding regimens needed. 73–76

People with asthma of all levels of severity are commonly exposed to allergens in the home. 50–57 Pet and cockroach sensitisation might be a marker for high morbidity, 78 although whether cockroach sensitisation can be separated from the effects of low socioeconomic status is arguable. 56 An interaction between passive smoking and pet sensitisation might exist. 79 The use of synthetic bedding might be associated with severe wheeze. 80 In our study of home visits, 70 children owned furry pets, 17 of whom were sensitised on skin prick testing, and only two implemented any allergen avoidance precautions. 31 Children had clinically significant exposure to house dust mites; five were taking comprehensive allergen avoidance measures, 15 were implementing partial measures, and 11 were adopting no measures. The association between allergen exposure, allergen sensitisation, and symptoms are complex and can vary from antigen to antigen. 90 An allergen can lead to symptoms even without evidence of specific IgE-mediated sensitisation. Nonetheless, in a child with severe symptoms of asthma, attempts to reduce environmental allergen exposure seems reasonable (we review such evidence later).

Psychosocial factors
The importance of acute and chronic stress as a trigger of asthma exacerbations is well recognised. 94–96 Stress amplifies the airway eosinophilic response to an allergen challenge. 97 In our study, 72 these triggers were common, particularly anxiety and depression, and most were only identified during discussions in the home. About half were referred to clinical psychology. Assessment of whether anxiety and depression are the cause or result of severe asthma is not productive; both are treated appropriately.

Comorbidities
In this section, we briefly outline some of the comorbidities associated with paediatric asthma.

Gastro-oesophageal reflex
The evidence that reflux causes asthma, and that treatment of reflux improves asthma, is of poor quality, with few adequately designed studies and small cohorts. 98–99 In our experience, treatment of apparently asymptomatic reflux in children with severe asthma is seldom helpful. However, we still deem it appropriate to exclude reflux as a comorbidity as part of our assessment because, on rare occasions, patients might improve on anti-reflux therapy (as discussed later).

Rhinosinusitis
Upper airway disease worsens quality of life and should be treated appropriately in any context. 99–102 Treatment of concomitant rhinosinusitis alleviates severe asthma in adults but whether similar treatment is effective in children is not clear.

Dysfunctional breathing
Vocal cord dysfunction and other forms of dysfunctional breathing are common in patients with asthma, and the symptoms are frequently wrongly attributed to asthma. This comorbidity is much less well studied in adults than in children. 103–105 In our series, 15% (11 of 71) had evidence of dysfunctional breathing, including hyperventilation and vocal cord dysfunction.

Dyspnoea perception has been little studied in severe paediatric asthma, 96 but in adults with severe asthma, patients do not become as dyspnoeic as those with mild asthma during bronchoconstriction. 97

Obesity
The interactions between obesity and asthma are complex. Obesity might cause diagnostic confusion (breathlessness without evidence of asthma), a pauci-inflammatory form
of asthma, and steroid resistance. Asthma and its treatment might contribute to obesity (oral steroid bursts, immobility). For these reasons, particular care is necessary in the management of children who are obese with respiratory symptoms. Weight reduction is always beneficial, but is difficult to achieve.

**Food allergy**

Asthmatics with a food allergy are over-represented in cohorts of children with severe asthma. Whether food allergy is causative or shares a common pathway is unclear. It would seem sensible to err on the side of overtreatment of a child with asthma who has a documented food allergy.

**Multidisciplinary team discussion**

Our recommended next step is discussion of the assessment by the multidisciplinary team. The aim is to decide whether further invasive investigations are justified and, if not, to develop a plan to address the reversible factors identified. In 55% of children (39 of 71), no further investigations were undertaken. Unfortunately, this percentage does not mean that the problem is necessarily solved; identification of poor adherence as a problem is different to resolving the problem itself. There is also evidence that interventions within the caregiver-patient relationship, which are costly in time and resources, might improve adherence. Data from large community studies (but not in patients with severe asthma) suggest that this sort of individualised, multifaceted environmental intervention is beneficial and cost effective, with benefits continuing for at least 1 year after the intervention has ceased. The more drastic step of taking children with asthma out of their environment altogether was unsuccessful in only five of 60 children. Psychological interventions might be effective, although, in general, individualised plans work best.

Our data have important implications for the interpretation of other studies. Cohorts of children with severe asthma who have not gone through a detailed filtering process will include at least 50% of children in whom the basic management needs have not been addressed, and results from these individuals might not be comparable to those with truly therapy-resistant asthma.

### The next steps: invasive investigation?

Once the clinician is satisfied that the basic management needs are right, there is even less evidence to help decide on the next steps. Our personal practice is to use a two-stage, invasive protocol. The aims of this protocol are to identify the following. (1) Whether there is an additional unsuspected diagnosis. (2) Whether there is discordance between symptoms and airway inflammation, particularly if the child is symptomatic with no evidence of inflammation. Giving patients increasingly potent anti-inflammatory drugs seems illogical if there is no residual inflammation left to treat. (3) The response to a single dose of intramuscular depot triamcinolone to assess whether there is at least partial steroid-resistant airway inflammation. (4) Whether there is evidence of non-eosinophilic, particularly neutrophilic inflammation.

We re-assess symptoms and the use of rescue treatment, FeNO, spirometry and bronchodilator response, and (if considered safe) induced sputum cytology. After the child undergoes fiberoptic bronchoscopy under general anaesthesia, bronchoalveolar lavage, and endobronchial biopsy, a pH probe is done, and intramuscular triamcinolone 80 mg is given. In the second stage, 3–4 weeks later, we repeat all the above non-invasive measurements, although a second bronchoscopy is not done. Finally, we develop an individualised treatment plan.

### Steroid responsiveness

There is no accepted definition of steroid resistance in children, and the mechanisms are unclear. Congenital steroid resistance from mutations in the corticosteroid receptor is rare. Acquired steroid resistance can extend over a range and can be overcome by high doses, albeit at the risk of increased side-effects. There are many potential mechanisms of steroid resistance, but these have been studied mostly in adults and the relevance in children is not clear. What is clear is that, despite high-dose inhaled and oral steroid therapy, children might have continuing symptoms and airway reactivity, even in the absence of proximal inflammation. The adult definition of steroid resistance (<15% increase in FEV1 after 2 weeks of oral prednisolone in a patient who can bronchodilate more than 15% with acute use of β2 agonists) is not appropriate for children, who can have normal spirometry despite severe asthma. Possible criteria are given in table 1. We also do not know the correct dose and duration of the steroid trial. For example, a 2-week course of prednisolone is not necessarily predictive of best lung function in children with asthma. We use parenteral steroids to ensure that adherence is complete.

---

<table>
<thead>
<tr>
<th>Requirement</th>
<th>Requirement</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Symptom response</strong></td>
<td>Asthma control test rises to a score of ≥20/25, or by at least 5 points</td>
</tr>
<tr>
<td>Lung function response</td>
<td>FEV1 rises to normal (≥−1.96 Z-score) or by ≥15%</td>
</tr>
<tr>
<td><strong>Inflammatory response</strong> (if paired induced sputum samples available)</td>
<td>Sputum eosinophil count normal (≤2.5%)</td>
</tr>
<tr>
<td><strong>Inflammatory response</strong> (if paired induced sputum samples not available)</td>
<td>Fractional exhaled nitric oxide* normal (&lt;24 parts per billion)</td>
</tr>
</tbody>
</table>

*Non-response is classified as no improvement in any domain; partial response is improvement in one or two domains; and complete response is normalisation in all three domains. Exhaled nitric oxide measured at flow 50 mL/s. FEV1 forced expired volume in 1 s.

Table 1: Possible criteria for steroid responsiveness in children with severe asthma.
Treatment of severe, therapy-resistant asthma

Unfortunately, treatment of severe, therapy-resistant asthma relies on a series of individual trials of single patients. In our clinical practice, we initially use drugs licensed in children before trying unlicensed and experimental therapy. Treatment strategies are summarised in tables 2 and 3, and some aspects are discussed in more detail later. This section reflects personal practice, not an evidence-based approach.

Treatment of eosinophilic inflammation

In our experience, the most common inflammatory pattern is eosinophilic inflammation, and this response persists after a single dose of triamcinolone in 50% of children.12 Options for treatment include: (1) high-dose inhaled corticosteroid; in severe asthma, the plateau of the dose-response curve might be increased,218 (2) the SMART regimen (combined budesonide and formoterol turbaholer as the only treatment), which might reduce exacerbations in particular119–121 and (3) further doses of triamcinolone.122

For children with persistent asthma, IgE-mediated sensitisation, and eosinophilic inflammation, despite tolerable levels of treatment and for whom every reasonable effort has been made to reduce the burden of allergen exposure, we next trial omalizumab.113–125 In many children, the IgE blood levels are higher than recommended for this therapy.24 We have still tried omalizumab in these children, but the likelihood of success is much lower if IgE levels are high. For children who do not respond to treatment, and continue to require high-dose systemic steroids, the only other option is steroid-sparing drugs such as methotrexate, azathioprine, or ciclosporin.122–128 Evidence of efficacy is confined to case series.

Treatment of the exacerabting phenotype

Acute asthma exacerbations cause substantial morbidity, sometimes death, and are an independent risk factor for an accelerated decline in lung function.26 These exacerbations cannot be abolished completely. Exacerbation and baseline control are not the same thing: loss of baseline control is characterised by wide diurnal peak expiratory flow variation, whereas acute exacerbation is indicated by a steep decline in peak flow, with no increased variability.116 Factors associated with exacerbations include extrinsic features, such as treatment non-compliance and psychosocial morbidities, and intrinsic factors such as poor production of interferons.129–131 Children might have good control, but can still have exacerbations,116 and increasing interval treatment only increases the risk of side-effects. However, poor control116 and previous severe exacerbations134,135 are both predictive of future acute exacerbations.

The exacerabting phenotype can cover a range of severities. In pre-school children who only wheeze with viral colds there is no evidence that allergens have any role. In older children, the combination of respiratory viral infection and both sensitisation and exposure in the home to high concentrations of allergens is strongly predictive of exacerbations in those with asthma.12 These exacerbations are typically characterised by mixed eosinophilic and neutrophilic inflammation, or pure neutrophilic inflammation.126–139 However, high-dose allergen exposure can cause acute exacerbations (eg, thunderstorm asthma139 and the soya bean asthma epidemic in Barcelona140), which are characterised by sputum eosinophilia.141 Data from studies in adults suggest that the exacerabting phenotype could be characterised by persistent sputum eosinophilia between exacerbations, and might respond to anti-interleukin-5 antibody.142,143

In school-age children with multiple exacerbations, we aim to increase the baseline dose of inhaled corticosteroid to abolish interval sputum eosinophilia. However, high-dose inhaled corticosteroids do not affect the severity of exacerbations. Long-acting β2 agonists also reduce numbers of exacerbation.131–135 Once allergen sensitisation is identified, avoidance measures can be advised. High-dose inhaled corticosteroids130 or leukotriene receptor antagonists131 can be considered at the first sign of a viral exacerbation. However, none of these measures will completely obviate the need for oral corticosteroids. Finally, if exacerbations are of sudden onset, with rapid deterioration over minutes, we provide the child with a source of injectable epinephrine (by use of an auto-injector). The hospital treatment of acute exacerbations is beyond the scope of this Review.7
Other treatment strategies

Many of the other treatment strategies include unlicensed and potentially dangerous therapies, and must be thoroughly discussed with the child and family, with the risks and benefits carefully taken into account.

For type 1 brittle asthma, the options are high-dose formoterol, often using a variant of the SMART regimen, or continuous subcutaneous infusion of terbutaline.146 In either case, the risks of high-dose β2 agonists should be discussed.147,148 If continuous subcutaneous terbutaline is used, we recommend that a double-blind trial is done in hospital; the child and family know that only the ward pharmacist will know which is the active treatment.

Persistent airflow limitation might be caused by genuine asthma, but is also commonly caused by oblitative bronchiolitis. Often, treatment has been escalated with no response. Treatment is reduced until there is evidence of airflow inflammation and bronchodilator reversibility.

Paucicellular asthma is common; only nine of 28 symptomatic children had evidence of cellular inflammation on induced sputum.46 Reduction of steroid therapy is recommended.

For neutrophilic asthma, we use oral theophyllines, which accelerate neutrophil apoptosis,150 and macrolides. Macrolides have proven value in other neutrophilic airway diseases,151–153 and there is some evidence of benefit in adult neutrophilic asthma.154,155 Finally, because corticosteroids inhibit neutrophil apoptosis,156 a cautious steroid taper might be worth considering. These options are only recommended for experienced specialists.

Severe asthma with fungal sensitisation is defined as severe asthma with evidence of sensitisation to one or more of seven fungi (as specified earlier).25 Allergic bronchopulmonary aspergillosis is rare in paediatric asthma, but fungal sensitisation is common. Fungal sensitisation can be associated with severe morbidity,260–262 and there should be a low threshold for scaling up therapy in affected children. In a randomised trial in adults with severe asthma with fungal sensitisation, benefit for itraconazole was reported.26 Data in children are sparse,263 but for those who meet adult criteria for severe asthma with fungal sensitisation, fungal exposure should probably be minimised and a trial of itraconazole or even voriconazole should be considered (although the risk of Cushing’s syndrome with inhaled corticosteroids and itraconazole should be kept in mind264).

Future treatment options

Future treatment options include therapies trialled in adults, and consideration of specific paediatric factors.

Anti-interleukin-5 antibody, other monoclonal antibodies, and bronchial thermoplasty all show promise in adults141,142,165,166 but there are no data in children. The value of carefully characterising patients rather than treating anyone with severe asthma is evident in adult studies of anti-interleukin-5;141,162 it is likely that this same careful approach will be needed for treatment of children.

The mechanisms of failure of normal airway growth, and subsequent accelerated decline in lung function, are unclear but probably involve airway remodelling. Current problems in treating airway remodelling include the absence of any biomarker, the difficulty in distinguishing changes that might actually be beneficial (reticular basement membrane thickening might be protective265), and the scarcity of any therapeutic interventions. Macrolides might possibly be used in the future.168 Although a recent study267 showed no benefit for add-on therapy with azithromycin, the number of participants was small, and although the authors concluded that a larger study would have revealed no benefit, ruling out the use of macrolides in every severe asthma phenotype on the basis of a single small trial would be premature.

Monitoring therapy

The use of home physiological monitoring and written treatment plans seems advisable, but there is little evidence for benefit in severe asthma.11,36 If perception of symptoms is poor, an objective measurement should be useful, but whether peak flow meters are sufficiently accurate, or likely to be used, is unknown. It is likely, but completely unproven, that compliance would be better in patients with severe rather than moderate asthma. We use home monitoring in these children, although with a poor evidence base.

Use of inflammatory markers to monitor severe asthma would probably be beneficial. In studies in patients with mild-to-moderate asthma, in whom it is less likely that the use of inflammatory markers will give added value, measurements of FeNO, bronchial responsiveness, and sputum eosinophils have been suggested to be useful to titrate therapy with inhaled corticosteroids, predict exacerbations, enable successful inhaled steroid reduction, and predict relapse after stopping inhaled corticosteroids.270–272 However, in a
randomised controlled trial of 55 children with severe asthma in which monitoring sputum eosinophils (or if sputum could not be produced, FeNO) was compared with a standard strategy, there were only non-significant trends for benefit. Reasons for this non-significance included unexpected phenotypic variability and the inconsistent association between FeNO and sputum eosinophils in this group. In adults, the eosinophilic and non-eosinophilic phenotypes seem stable. By contrast, 39% of children (17 of 44) had at least one switch in phenotype over 1 year. Although FeNO and sputum eosinophilia was used interchangeably in a study of adults with mild asthma, in children with severe asthma the association between the two biomarkers varied over time even in the same individual. There might be discordance (a high FeNO with normal sputum eosinophils, or a normal FeNO with high eosinophils) or concordance (both high or both normal), and all four combinations can be seen in the same individual. Because sputum induction is not possible in at least 20% of children, better biomarkers of airway eosinophilia than FeNO are needed.

Future perspectives
Current strategies mainly use sputum to monitor proximal airway luminal inflammation. However, other compartments might be important and discordant. In bronchoscopic studies in children, airway mucosal and luminal changes can be different, and it is unclear which is most important. We have no non-invasive biomarkers for mucosal inflammation. Distal airway inflammation may cause poorly controlled or nocturnal asthma. In a study of adults with mild asthma, in children with severe asthma the association between the two biomarkers varied over time even in the same individual. Finally, although CBV can be used to show differences between groups, there is such a degree of overlap that it is unlikely to be able to guide the use of treatment in an individual. Thus, we need information about the importance of proximal and distal tissue inflammation, and distal luminal inflammation, with regard to proximal luminal inflammation. Furthermore, we need information on non-invasive biomarkers that is robust enough to be of value in monitoring individuals. Biomarkers are needed to guide management, specifically to quickly identify children who are not doing well, and to identify responders (and, more importantly, non-responders) to innovative and potentially dangerous therapies.

Despite the interest in mechanisms, biomarkers, phenotypes, and novel treatment strategies for patients with severe, therapy-resistant asthma, the current best approach is thorough multidisciplinary assessment of children with problematic severe asthma, which should result in at least half of these children being successfully managed with conventional treatments.

Contributors
AB wrote the initial draft of the paper. Both authors reviewed subsequent revisions and the final version of this Review.

Conflicts of interest
We declare that we have no conflicts of interest.

References

www.thelancet.com Vol 376 September 4, 2010 821


